Torrent Pharmaceuticals and Temasek-backed Intas are the latest to join the race, to acquire a band of products in Europe put on the block by Teva, the world’s largest generic drug maker. The deal, said to be valued up to $1.5 billion, has seen the Hyderabad-based Aurobindo Pharma emerge as one of the front runners in the initial rounds. The drug maker is currently working on ways to mop up finances for the deal, should it make the cut, three people familiar with the developments.
Sun Pharma Advanced Research Company Ltd (SPARC) and Sun Pharma announced a licensing arrangement for SPARC's ELEPSIA XR (Levetiracetam ER Tablets). As per arrangement, SPARC will license ELEPSIA XR (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma for the US market.
Torrent Pharmaceuticals and Temasek-backed Intas are the latest to join the race, to acquire a band of products in Europe put on the block by Teva, the world’s largest generic drug maker. The deal, said to be valued up to $1.5 billion, has seen the Hyderabad-based Aurobindo Pharma emerge as one of the front runners in the initial rounds. The drug maker is currently working on ways to mop up finances for the deal, should it make the cut, three people familiar with the developments. (ET)
Dr Reddy's Laboratories expects complex generics, proprietary products, including creation of branded generics platform in the US, to be the main drivers of its growth going forward. (FC)
Glenmark Pharmaceuticals Ltd has informed BSE that subsequent to the rating received by the leading credit agencies in the world i.e. S&P and Fitch, Glenmark Pharmaceuticals limited has decided to tap into the International Bond market and is planning to raise around USD 200 mn by issuing USD denominated non-convertible unsecured bonds.
JB Chemicals & Pharmaceuticals Ltd has announced that this has reference to disclosures earlier made in relation to Order dated 8-1-2016 passed by National Green Tribunal (NGT) which, inter alia, directed the closure of industrial activities at the Company’s built drugs plant at Panoli, Gujarat. We also refer to disclosure made on May 19, 2016 informing the Exchange that NGT by Judgement and Order dated 17-5-2016 did not allow the Company’s Application for review of the Order passed on 8-1-2016 (Collectively the Orders).
US brokerage firm Jefferies said India's pharma sector may report strong revenue growth for the June quarter. It expects revenue growth of 17 per cent, led by exclusivity launches. (FC)
A second laboratory on the premises of Avon Lifesciences Ltd, from where nearly 20 tonnes of Ephedrine was seized recently, has attracted the attention of the Thane police. Investigators had alleged that the firm was diverting Ephedrine, a controlled substance used to make medicines, to drug cartels to cook the make party drug Meth. An officer linked to the probe said, “The company has one laboratory for production purposes. While conducting searches at the premises, we found a second laboratory, which appears to have been set up some time ago. When we asked why the second laboratory was needed, we did not get a convincing answer.” (IE)
Torrent Pharmaceuticals and Temasek-backed Intas are the latest to join the race, to acquire a band of products in Europe put on the block by Teva, the world’s largest generic drug maker. The deal, said to be valued up to $1.5 billion, has seen the Hyderabad-based Aurobindo Pharma emerge as one of the front runners in the initial rounds. The drug maker is currently working on ways to mop up finances for the deal, should it make the cut, three people familiar with the developments. (ET)
Dr Reddy's Laboratories expects complex generics, proprietary products, including creation of branded generics platform in the US, to be the main drivers of its growth going forward. (FC)
Glenmark Pharmaceuticals Ltd has informed BSE that subsequent to the rating received by the leading credit agencies in the world i.e. S&P and Fitch, Glenmark Pharmaceuticals limited has decided to tap into the International Bond market and is planning to raise around USD 200 mn by issuing USD denominated non-convertible unsecured bonds.
JB Chemicals & Pharmaceuticals Ltd has announced that this has reference to disclosures earlier made in relation to Order dated 8-1-2016 passed by National Green Tribunal (NGT) which, inter alia, directed the closure of industrial activities at the Company’s built drugs plant at Panoli, Gujarat. We also refer to disclosure made on May 19, 2016 informing the Exchange that NGT by Judgement and Order dated 17-5-2016 did not allow the Company’s Application for review of the Order passed on 8-1-2016 (Collectively the Orders).
US brokerage firm Jefferies said India's pharma sector may report strong revenue growth for the June quarter. It expects revenue growth of 17 per cent, led by exclusivity launches. (FC)
A second laboratory on the premises of Avon Lifesciences Ltd, from where nearly 20 tonnes of Ephedrine was seized recently, has attracted the attention of the Thane police. Investigators had alleged that the firm was diverting Ephedrine, a controlled substance used to make medicines, to drug cartels to cook the make party drug Meth. An officer linked to the probe said, “The company has one laboratory for production purposes. While conducting searches at the premises, we found a second laboratory, which appears to have been set up some time ago. When we asked why the second laboratory was needed, we did not get a convincing answer.” (IE)
No comments:
Post a Comment